Clinical Trial News and Research

RSS

Researchers develop new technique to detect lung cancer

Early detection is critical for improving cancer survival rates. Yet, one of the deadliest cancers in the United States, lung cancer, is notoriously difficult to detect in its early stages.

8 Oct 2010

Targacept announces top-line results from AZD1446 Phase 2 clinical trial for ADHD

Targacept, Inc. today announced top-line results from a Phase 2 clinical trial of AZD1446 conducted by AstraZeneca in adults with attention deficit/hyperactivity disorder (ADHD).

8 Oct 2010

Onyx Pharmaceuticals announces delay in NDA filing for carfilzomib

Onyx Pharmaceuticals, Inc. today announced that it will delay its New Drug Application (NDA) filing for carfilzomib based on a recent meeting with the Chemistry, Manufacturing and Controls (CMC) review division of the U.S. Food and Drug Administration (FDA).

7 Oct 2010

Cepheid collaborates with Novartis to commercialize BCR-ABL monitoring test

Cepheid today announced an exclusive collaboration with Novartis for the commercialization of a test for monitoring the BCR-ABL gene transcript in peripheral blood specimens from patients diagnosed with Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML). Together with other lab tests, monitoring levels of BCR-ABL transcripts in Ph+ CML patients will aid in patient management.

7 Oct 2010

Bayer HealthCare, Onyx to present data on Nexavar tablets at ESMO Congress

Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that more than 20 studies evaluating the use of Nexavar® (sorafenib) tablets will be presented at the 35th European Society for Medical Oncology (ESMO) Congress, October 8-12, 2010 in Milan, Italy.

7 Oct 2010

IDEV Technologies completes $46 million Series D round of financing with PJC Capital

IDEV Technologies, Incorporated, an emerging leader in the development and commercialization of minimally invasive medical technologies, today announced that it has completed a $46 million Series D round of financing, with Piper Jaffray & Co.'s Merchant Banking Fund and a leading strategic global healthcare company as the two new investors.

7 Oct 2010

Integra to present multi-center study of peripheral nerve repair at Mexico joint meeting

Integra LifeSciences Holdings Corporation announced today that the results of the multi-center human clinical trial comparing NeuraGen Nerve Guide with direct suture repair have been accepted, in abstract form, for presentation at the joint meeting of the American Association for Hand Surgery (AAHS), American Society for Reconstructive Microsurgery (ASRM), and American Society for Peripheral Nerve (ASPN), January 12-18, 2011, Cancun Mexico.

7 Oct 2010

Vaccine improves survival of glioblastoma patients in phase II clinical trial: Researchers

A vaccine that turns the immune system against brain tumor cells bearing a genetic mutation that drives the most aggressive form of glioblastoma multiforme improved survival of patients in a phase II clinical trial, researchers at Duke University and The University of Texas MD Anderson Cancer Center reported today in the Journal of Clinical Oncology.

7 Oct 2010

Surgeons create novel matrix to control insulin dependent diabetes

Surgeons from Massachusetts General Hospital, Boston, are reporting on a whole new strategy for controlling insulin dependent diabetes without daily injections of insulin. The surgeons have bio-engineered a novel matrix that serves as a scaffold for seeding supportive stem cells as well as pancreatic islets (the cells that produce insulin in the pancreas).

7 Oct 2010

Ferring Pharmaceuticals announces publication of Phase 3 trials of LYSTEDA tablets for HMB

Ferring Pharmaceuticals Inc. today announced publication of one of its pivotal Phase 3 trials of LYSTEDA (tranexamic acid) tablets for cyclic heavy menstrual bleeding in the October issue of the peer-reviewed journal, Obstetrics & Gynecology. The six-month clinical trial demonstrated that LYSTEDA significantly reduced menstrual blood loss from baseline, and improved health-related quality-of-life parameters in women with cyclic HMB while maintaining safety and tolerability.

7 Oct 2010

New microtechnology approach may prevent pelvic autonomic nerve injury in rectal cancer surgical procedure

Surgeons in Germany have found that using microtechnology to elec-tronically stimulate and monitor pelvic autonomic nerves may help prevent problems after a surgical procedure for rectal cancer, such as bladder, urinary and fecal incontinence, and sexual function disorders, according to a study reported at the 2010 Annual Clinical Congress of the American College of Surgeons.

7 Oct 2010

Patients with muscular dystrophy mount immune response to dystophin protein prior to gene therapy: Study

A clinical trial designed to replace the genetic defect causing the most common form of muscular dystrophy has uncovered an unexpected aspect of the disease. The trial, based on therapy designed by scientists at the University of North Carolina at Chapel Hill School of Medicine, showed that some patients mount an immune response to the dystrophin protein even before they have received the gene therapy.

7 Oct 2010

BIOTRONIK's EchoCRT clinical trial design published in European Heart Journal

BIOTRONIK SE & Co. KG, a leading manufacturer of implantable cardiac devices and sponsor of clinical research to advance patient care and evidence-based medicine, announced the publication in the September 23, 2010 issue of the European Heart Journal of a peer-reviewed article that describes the rationale for the echocardiographic methods and dyssynchrony cutoff values selected for the EchoCRT study.

6 Oct 2010

Synergy reports positive results from plecanatide Phase IIa clinical trial for chronic constipation

Synergy Pharmaceuticals, Inc., a developer of new drugs to treat gastrointestinal disorders and diseases, announced today positive results in a Phase IIa clinical trial of plecanatide (SP-304) in patients with chronic constipation. Oral plecanatide given once daily, over 14 consecutive days, at doses of 0.3, 1.0, 3.0 and 9.0 mg gave improved bowel function in patients with chronic constipation.

6 Oct 2010

Adeona completes enrollment in Part 2 CopperProof-2 clinical study

Adeona Pharmaceuticals, Inc., announced completion of 100% enrollment in Part 2 of its clinical study, A Prospective, Randomized, Double Blind Trial of a Novel Oral Zinc Cysteine Preparation in Alzheimer's Disease (CopperProof-2).

6 Oct 2010

Innovacell invests 10 million Euros for clinical development

In a new round of financing, shareholders of Innsbruck's Innovacell Biotechnologie AG agreed on September 27th to make 4.3 million Euros worth of fresh capital available to the company. Financing of the current Phase IIb multi-centre study for urocell is thus totally secured," explained CEO Ekkehart Steinhuber.

6 Oct 2010

Hypertonic fluids do not improve outcomes or survival for severe traumatic brain injury: Study

Patients with a severe traumatic brain injury (and not in shock because of blood loss) who received out-of-hospital administration of hypertonic fluids (a solution with increased concentration of certain electrolytes and thought to help reduce intracranial pressure) as initial resuscitation did not experience better 6-month neurologic outcomes or survival compared to patients who received a normal saline solution, according to a study in the October 6 issue of JAMA.

6 Oct 2010

Focused Ultrasound Surgery Foundation hosts conference to discuss advancements in therapeutic medicine

The Focused Ultrasound Surgery Foundation is hosting the 2nd International Symposium on MR-guided Focused Ultrasound in Chantilly, Virginia from October 17-20. Leading researchers and clinicians from around the world will gather at the three-day scientific conference to present and discuss the latest advancements in one of the most revolutionary and promising areas of therapeutic medicine.

6 Oct 2010

Aegerion Pharmaceuticals’ MTP-I Phase III trial published in Atherosclerosis online supplement

ACR Image Metrix, a global imaging contract research organization (CRO) with expertise in imaging trial design, techniques and data extraction, is pleased to announce a Phase III trial, conducted for Aegerion Pharmaceuticals, Inc., was published as an abstract in the online supplement of Atherosclerosis and presented at the 78th European Atherosclerosis Society Congress, which took place June 20-23, 2010, in Hamburg, Germany.

6 Oct 2010

New Wipro Rapid Trials platform launched to accelerate drug development

Wipro Technologies, the global Consulting, System Integration and Outsourcing business of Wipro Limited, today announced the launch of Wipro Rapid Trials platform to accelerate drug development across the globe.

6 Oct 2010

Clinical Trial News and Research

Researchers develop new technique to detect lung cancer

Targacept announces top-line results from AZD1446 Phase 2 clinical trial for ADHD

Onyx Pharmaceuticals announces delay in NDA filing for carfilzomib

Cepheid collaborates with Novartis to commercialize BCR-ABL monitoring test

Bayer HealthCare, Onyx to present data on Nexavar tablets at ESMO Congress

IDEV Technologies completes $46 million Series D round of financing with PJC Capital

Integra to present multi-center study of peripheral nerve repair at Mexico joint meeting

Vaccine improves survival of glioblastoma patients in phase II clinical trial: Researchers

Surgeons create novel matrix to control insulin dependent diabetes

Ferring Pharmaceuticals announces publication of Phase 3 trials of LYSTEDA tablets for HMB

New microtechnology approach may prevent pelvic autonomic nerve injury in rectal cancer surgical procedure

Patients with muscular dystrophy mount immune response to dystophin protein prior to gene therapy: Study

BIOTRONIK's EchoCRT clinical trial design published in European Heart Journal

Synergy reports positive results from plecanatide Phase IIa clinical trial for chronic constipation

Adeona completes enrollment in Part 2 CopperProof-2 clinical study

Innovacell invests 10 million Euros for clinical development

Hypertonic fluids do not improve outcomes or survival for severe traumatic brain injury: Study

Focused Ultrasound Surgery Foundation hosts conference to discuss advancements in therapeutic medicine

Aegerion Pharmaceuticals’ MTP-I Phase III trial published in Atherosclerosis online supplement

New Wipro Rapid Trials platform launched to accelerate drug development

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News